October 28, 2020DiabetesOpen Access

Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench

View Full Paper

Ask AI

Bookmark

Why the study?

Although dapagliflozin demonstrates benefits in symptomatic heart failure, the underlying mechanisms remain largely unknown.

Does dapagliflozin improve subclinical myocardial function in patients with diabetes free from symptomatic heart failure?

Population

Patients with diabetes free from symptomatic heart failure and streptozotocin-induced diabetic rats

Comparison

Dapagliflozin treatment vs baseline or controls

Design

Longitudinal prospective clinical and translational study

Follow-up

6 months

Authors

JSJhih‐Yuan ShihNational Sun Yat-sen University YLYu‐Wen LinCentral South University SFSudeshna FischBrigham and Women's Hospital

Discussion

Member takes

Implication

Dapagliflozin-linked LV strain changes in diabetes without HF should not yet change practice; leaves open causal benefits on subclinical dysfunction.

Structured PICO

Does dapagliflozin improve subclinical myocardial function in patients with diabetes free from symptomatic heart failure?

Population

Patients with diabetes free from symptomatic heart failure; streptozotocin-induced diabetic rat model; in vitro cardiomyocytes under high glucose.

Intervention

Dapagliflozin (6 months for clinical cohort)

Comparator

Pre-treatment baseline (clinical cohort); control and insulin (preclinical rat model)

Outcome

Changes in left ventricular function including speckle tracking (diastolic function, longitudinal strain, LVEF)surrogate

Dapagliflozin improves subclinical myocardial function in diabetic patients and mitigates myocardial fibrosis and ER stress in preclinical models.

Cite This Study

Shih et al. (2020) studied this question.

synapsesocial.com/papers/6a484ddda567c8cbc92f7dd8 https://doi.org/10.2337/db20-0840

Topics

SGLT2 inhibitors in heart failure

View Full Paper

Ask AI

Bookmark

Implication

Dapagliflozin-linked LV strain changes in diabetes without HF should not yet change practice; leaves open causal benefits on subclinical dysfunction.

Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider